The Thalassemia and Hereditary Blood Disorders Care Center has concluded the distribution of health sponsorships for patients during the period from October 20 to November 5, 2018. A total of 350 patients benefited from the program, which was funded by Silah Foundation for Humanitarian Development. This support comes as a lifesaving intervention for dozens of registered patients amidst the ongoing crisis in the country.
These sponsorships include essential medications that play a critical role in reducing the complications of chronic hereditary blood diseases.
Mr. Jameel Al-Khayyati, Executive Director of the Yemeni Society for Thalassemia Patients, emphasized that the center is unable to provide medications continuously due to the lack of government support, soaring drug prices, and the increasing number of registered patients—many of whom are displaced from other governorates.
One of the beneficiaries, a woman in her early thirties, stated:
“I rely on Hydroxyurea as a primary treatment on a daily basis. When the dose is unavailable, I suffer excruciating pain that prevents me from working. This support from Silah Foundation has eased our suffering, as we cannot afford the original medication due to its high price, and the alternatives are often ineffective. We extend our deepest thanks to the Center and to Silah Foundation for this generous and humane initiative.”
It is worth noting that the patients registered at the center require comprehensive healthcare services and a consistent supply of vital medications. This reality calls for the collaboration of all concerned institutions and charitable organizations to ensure adequate financial and material support for these patients. .
